The study further showed that WWP2 is a direct target of Wnt/β-catenin signaling pathway, and that DKK1 suppresses the expression of WWP2 by blocking the canonical Wnt signaling to promote Gli stabilization and Hh pathway activation, which may contribute to DKK1-mediated drug resistance in bortezomib-based chemotherapy of multiple myeloma [63]. Here, WWP2 is linked to plasma cell myeloma.